Skip to main content
SpringerLink
Log in

Epidemiology of Ovarian Cancer: An Update

  • Chapter
  • First Online:
Advances in Diagnosis and Management of Ovarian Cancer

Abstract

Ovarian cancer (OC) is the eighth most commonly diagnosed cancer among women in the world and represents the most lethal gynecologic malignancy. Wide geographic variation exists in OC incidence and mortality, with the highest age-adjusted incidence (11.8 per 100,000) and mortality rates (6.5 per 100,000) observed in developed regions such as Europe and North America; trends suggest OC incidence and mortality is gradually declining in these regions. Factors associated with elevated risk include older age and having a family history of the disease. Conversely, several factors confer decreased risk, including increasing parity, oral contraceptive use, and oophorectomy. Lactation, incomplete pregnancies, and surgeries such as hysterectomy and tubal ligation may confer a weak, protective effect against OC. Infertility may contribute to OC risk among nulliparous women. Other possible risk factors for OC include postmenopausal hormone replacement therapy and lifestyle factors such as cigarette smoking and alcohol consumption. Knowledge of the epidemiology of the disease can help inform primary prevention, early detection, and possibly even therapeutic strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v 1.2: Cancer incidence, mortality, and prevalence worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer. Available from: http://globocan.iarc.fr. Accessed on 12/18/11. 2008.

    Google Scholar 

  2. Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol. 2006;20(2):207–25.

    CAS  PubMed  Google Scholar 

  3. Ahlgren JD. Epidemiology and risk factors in pancreatic cancer. Semin Oncol. 1996;23(2):241–50.

    CAS  PubMed  Google Scholar 

  4. Howlader NNA, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK (eds). SEER cancer statistics review, 1975–2008, National Cancer Institute. Bethesa, MD, http://seer.cancer.gov/csr/1975_2008/. Based on November 2010 SEER data submission, posted to the SEER website, 2011.

  5. Chen VW, Ruiz B, Killeen JL, Cote TR, Wu XC, Correa CN. Pathology and classification of ovarian tumors. Cancer. 2003;97(10 Suppl):2631–42.

    PubMed  Google Scholar 

  6. Weiss NS, Cook LS, Farrow DC, Rosenblatt KA. Ovarian cancer. In: Schottenfeld D, Fraumeni JF, editors. Cancer epidemiology and prevention. New York: Oxford University Press; 1996. p. 1040–57.

    Google Scholar 

  7. McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology. 2011;43(5):420–32.

    PubMed  Google Scholar 

  8. Seidman JD, Horkayne-Szakaly I, Haiba M, Boice CR, Kurman RJ, Ronnett BM. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol. 2004;23(1):41–4.

    PubMed  Google Scholar 

  9. Kobel M, Kalloger SE, Huntsman DG, et al. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol. 2010;29(3):203–11.

    PubMed  Google Scholar 

  10. Eltabbakh GH, Natarajan N, Piver MS, Mettlin CJ. Epidemiologic differences between women with borderline ovarian tumors and women with epithelial ovarian cancer. Gynecol Oncol. 1999;74(1):103–7.

    CAS  PubMed  Google Scholar 

  11. Tung KH, Goodman MT, Wu AH, et al. Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study. Am J Epidemiol. 2003;158(7):629–38.

    PubMed  Google Scholar 

  12. Marchbanks PA, Wilson H, Bastos E, Cramer DW, Schildkraut JM, Peterson HB. Cigarette smoking and epithelial ovarian cancer by histologic type. Obstet Gynecol. 2000;95(2):255–60.

    CAS  PubMed  Google Scholar 

  13. Risch HA, Marrett LD, Jain M, Howe GR. Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. Am J Epidemiol. 1996;144(4):363–72.

    CAS  PubMed  Google Scholar 

  14. Chiaffarino F, Parazzini F, Bosetti C, et al. Risk factors for ovarian cancer histotypes. Eur J Cancer. 2007;43(7):1208–13.

    PubMed  Google Scholar 

  15. Kurian AW, Balise RR, McGuire V, Whittemore AS. Histologic types of epithelial ovarian cancer: have they different risk factors? Gynecol Oncol. 2005;96(2):520–30.

    PubMed  Google Scholar 

  16. Parazzini F, Chiaffarino F, Negri E, et al. Risk factors for different histological types of ovarian cancer. Int J Gynecol Cancer. 2004;14(3):431–6.

    CAS  PubMed  Google Scholar 

  17. Gates MA, Rosner BA, Hecht JL, Tworoger SS. Risk factors for epithelial ovarian cancer by histologic subtype. Am J Epidemiol. 2010;171(1):45–53.

    PubMed  Google Scholar 

  18. Herrinton LJ, Stanford JL, Schwartz SM, Weiss NS. Ovarian cancer incidence among Asian migrants to the United States and their descendants. J Natl Cancer Inst. 1994;86(17):1336–9.

    CAS  PubMed  Google Scholar 

  19. Kliewer EV, Smith KR. Ovarian cancer mortality among immigrants in Australia and Canada. Cancer Epidemiol Biomarkers Prev. 1995;4(5):453–8.

    CAS  PubMed  Google Scholar 

  20. Bray F, Loos AH, Tognazzo S, La Vecchia C. Ovarian cancer in Europe: cross-sectional trends in incidence and mortality in 28 countries, 1953–2000. Int J Cancer. 2005;113(6):977–90.

    CAS  PubMed  Google Scholar 

  21. Coleman MP, Esteve J, Damiecki P, Arslan A, Renard H. Trends in cancer incidence and mortality. IARC Sci Publ. 1993;121:1–806.

    PubMed  Google Scholar 

  22. Howe HL, Wu X, Ries LA, et al. Annual report to the nation on the status of cancer, 1975–2003, featuring cancer among U.S. Hispanic/Latino populations. Cancer. 2006;107(8):1711–42.

    PubMed  Google Scholar 

  23. Nguyen HN, Averette HE, Janicek M. Ovarian carcinoma. A review of the significance of familial risk factors and the role of prophylactic oophorectomy in cancer prevention. Cancer. 1994;74(2):545–55.

    CAS  PubMed  Google Scholar 

  24. Parazzini F, Negri E, La Vecchia C, Restelli C, Franceschi S. Family history of reproductive cancers and ovarian cancer risk: an Italian case-control study. Am J Epidemiol. 1992;135(1):35–40.

    CAS  PubMed  Google Scholar 

  25. Stratton JF, Pharoah P, Smith SK, Easton D, Ponder BA. A systematic review and meta-analysis of family history and risk of ovarian cancer. Br J Obstet Gynaecol. 1998;105(5):493–9.

    CAS  PubMed  Google Scholar 

  26. Sutcliffe S, Pharoah PD, Easton DF, Ponder BA. Ovarian and breast cancer risks to women in families with two or more cases of ovarian cancer. Int J Cancer. 2000;87(1):110–7.

    CAS  PubMed  Google Scholar 

  27. Ziogas A, Gildea M, Cohen P, et al. Cancer risk estimates for family members of a population-based family registry for breast and ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2000;9(1):103–11.

    CAS  PubMed  Google Scholar 

  28. Negri E, Pelucchi C, Franceschi S, et al. Family history of cancer and risk of ovarian cancer. Eur J Cancer. 2003;39(4):505–10.

    CAS  PubMed  Google Scholar 

  29. Lynch HT, Casey MJ, Snyder CL, et al. Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Mol Oncol. 2009;3(2):97–137.

    CAS  PubMed  Google Scholar 

  30. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet. 1994;343(8899):692–5.

    CAS  PubMed  Google Scholar 

  31. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117–30.

    CAS  PubMed  Google Scholar 

  32. Malander S, Ridderheim M, Masback A, et al. One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden. Eur J Cancer. 2004;40(3):422–8.

    CAS  PubMed  Google Scholar 

  33. Menkiszak J, Gronwald J, Gorski B, et al. Hereditary ovarian cancer in Poland. Int J Cancer. 2003;106(6):942–5.

    CAS  PubMed  Google Scholar 

  34. Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005;104(12):2807–16.

    CAS  PubMed  Google Scholar 

  35. Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001;68(3):700–10.

    CAS  PubMed  Google Scholar 

  36. Stratton JF, Gayther SA, Russell P, et al. Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med. 1997;336(16):1125–30.

    CAS  PubMed  Google Scholar 

  37. Takahashi H, Behbakht K, McGovern PE, et al. Mutation analysis of the BRCA1 gene in ovarian cancers. Cancer Res. 1995;55(14):2998–3002.

    CAS  PubMed  Google Scholar 

  38. Anton-Culver H, Cohen PF, Gildea ME, Ziogas A. Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer. Eur J Cancer. 2000;36(10):1200–8.

    CAS  PubMed  Google Scholar 

  39. Bjorge T, Lie AK, Hovig E, et al. BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study. Br J Cancer. 2004;91(10):1829–34.

    CAS  PubMed  Google Scholar 

  40. Van Der Looij M, Szabo C, Besznyak I, et al. Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary. Int J Cancer. 2000;86(5):737–40.

    Google Scholar 

  41. Lynch HT, Smyrk T. Hereditary nonpolyposis colorectal cancer (Lynch syndrome). An updated review. Cancer. 1996;78(6):1149–67.

    CAS  PubMed  Google Scholar 

  42. Aarnio M, Mecklin JP, Aaltonen LA, Nystrom-Lahti M, Jarvinen HJ. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer. 1995;64(6):430–3.

    CAS  PubMed  Google Scholar 

  43. Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer. 1999;81(2):214–8.

    CAS  PubMed  Google Scholar 

  44. Prat J, Ribe A, Gallardo A. Hereditary ovarian cancer. Hum Pathol. 2005;36(8):861–70.

    CAS  PubMed  Google Scholar 

  45. Bonadona V, Bonaiti B, Olschwang S, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. 2011;305(22):2304–10.

    CAS  PubMed  Google Scholar 

  46. Boyd J, Rubin SC. Hereditary ovarian cancer: molecular genetics and clinical implications. Gynecol Oncol. 1997;64(2):196–206.

    CAS  PubMed  Google Scholar 

  47. Lynch HT, Casey MJ, Shaw TG, Lynch JF. Hereditary factors in gynecologic cancer. Oncologist. 1998;3(5):319–38.

    PubMed  Google Scholar 

  48. Fasching PA, Gayther S, Pearce L, et al. Role of genetic polymorphisms and ovarian cancer susceptibility. Mol Oncol. 2009;3(2):171–81.

    CAS  PubMed  Google Scholar 

  49. Bolton KL, Tyrer J, Song H, et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet. 2010;42:880–4.

    CAS  PubMed  Google Scholar 

  50. Goode EL, Chenevix-Trench G, Song H, et al. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet. 2010;42:874–9.

    CAS  PubMed  Google Scholar 

  51. Song H, Ramus SJ, Tyrer J, et al. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet. 2009;41(9):996–1000.

    CAS  PubMed  Google Scholar 

  52. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst. 1998;90(23):1774–86.

    CAS  PubMed  Google Scholar 

  53. Casagrande JT, Louie EW, Pike MC, Roy S, Ross RK, Henderson BE. “Incessant ovulation” and ovarian cancer. Lancet. 1979;2(8135):170–3.

    CAS  PubMed  Google Scholar 

  54. Tung KH, Wilkens LR, Wu AH, et al. Effect of anovulation factors on pre- and postmenopausal ovarian cancer risk: revisiting the incessant ovulation hypothesis. Am J Epidemiol. 2005;161(4):321–9.

    PubMed  Google Scholar 

  55. Moorman PG, Schildkraut JM, Calingaert B, Halabi S, Vine MF, Berchuck A. Ovulation and ovarian cancer: a comparison of two methods for calculating lifetime ovulatory cycles (United States). Cancer Causes Control. 2002;13(9):807–11.

    PubMed  Google Scholar 

  56. Schildkraut JM, Moorman PG, Bland AE, et al. Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroup. Cancer Epidemiol Biomarkers Prev. 2008;17(3):585–93.

    CAS  PubMed  Google Scholar 

  57. Terry KL, Titus-Ernstoff L, McKolanis JR, Welch WR, Finn OJ, Cramer DW. Incessant ovulation, mucin 1 immunity, and risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(1):30–5.

    CAS  PubMed  Google Scholar 

  58. Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst. 1983;71(4):717–21.

    CAS  PubMed  Google Scholar 

  59. Riman T, Persson I, Nilsson S. Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence. Clin Endocrinol (Oxf). 1998;49(6):695–707.

    CAS  Google Scholar 

  60. Booth M, Beral V, Smith P. Risk factors for ovarian cancer: a case-control study. Br J Cancer. 1989;60(4):592–8.

    CAS  PubMed  Google Scholar 

  61. Franceschi S, La Vecchia C, Booth M, et al. Pooled analysis of 3 European case-control studies of ovarian cancer: II. Age at menarche and at menopause. Int J Cancer. 1991;49(1):57–60.

    CAS  PubMed  Google Scholar 

  62. Parazzini F, Franceschi S, La Vecchia C, Fasoli M. The epidemiology of ovarian cancer. Gynecol Oncol. 1991;43(1):9–23.

    CAS  PubMed  Google Scholar 

  63. Parazzini F, La Vecchia C, Negri E, Gentile A. Menstrual factors and the risk of epithelial ovarian cancer. J Clin Epidemiol. 1989;42(5):443–8.

    CAS  PubMed  Google Scholar 

  64. Purdie D, Green A, Bain C, et al. Reproductive and other factors and risk of epithelial ovarian cancer: an Australian case-control study. Survey of Women’s Health Study Group. Int J Cancer. 1995;62(6):678–84.

    CAS  PubMed  Google Scholar 

  65. Tavani A, Negri E, Franceschi S, Parazzini F, La Vecchia C. Risk factors for epithelial ovarian cancer in women under age 45. Eur J Cancer. 1993;29A(9):1297–301.

    CAS  PubMed  Google Scholar 

  66. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol. 1992;136(10):1184–203.

    CAS  PubMed  Google Scholar 

  67. Wu ML, Whittemore AS, Paffenbarger Jr RS, et al. Personal and environmental characteristics related to epithelial ovarian cancer. I. Reproductive and menstrual events and oral contraceptive use. Am J Epidemiol. 1988;128(6):1216–27.

    CAS  PubMed  Google Scholar 

  68. Wynder EL, Dodo H, Barber HR. Epidemiology of cancer of the ovary. Cancer. 1969;23(2):352–70.

    CAS  PubMed  Google Scholar 

  69. Hankinson SE, Colditz GA, Hunter DJ, et al. A prospective study of reproductive factors and risk of epithelial ovarian cancer. Cancer. 1995;76(2):284–90.

    CAS  PubMed  Google Scholar 

  70. Risch HA, Marrett LD, Howe GR. Parity, contraception, infertility, and the risk of epithelial ovarian cancer. Am J Epidemiol. 1994;140(7):585–97.

    CAS  PubMed  Google Scholar 

  71. Shu XO, Brinton LA, Gao YT, Yuan JM. Population-based case-control study of ovarian cancer in Shanghai. Cancer Res. 1989;49(13):3670–4.

    CAS  PubMed  Google Scholar 

  72. Tzonou A, Day NE, Trichopoulos D, et al. The epidemiology of ovarian cancer in Greece: a case-control study. Eur J Cancer Clin Oncol. 1984;20(8):1045–52.

    CAS  PubMed  Google Scholar 

  73. Kvale G, Heuch I, Nilssen S, Beral V. Reproductive factors and risk of ovarian cancer: a prospective study. Int J Cancer. 1988;42(2):246–51.

    CAS  PubMed  Google Scholar 

  74. McGowan L, Norris HJ, Hartge P, Hoover R, Lesher L. Risk factors in ovarian cancer. Eur J Gynaecol Oncol. 1988;9(3):195–9.

    CAS  PubMed  Google Scholar 

  75. Newhouse ML, Pearson RM, Fullerton JM, Boesen EA, Shannon HS. A case control study of carcinoma of the ovary. Br J Prev Soc Med. 1977;31(3):148–53.

    CAS  PubMed  Google Scholar 

  76. Polychronopoulou A, Tzonou A, Hsieh CC, et al. Reproductive variables, tobacco, ethanol, coffee and somatometry as risk factors for ovarian cancer. Int J Cancer. 1993;55(3):402–7.

    CAS  PubMed  Google Scholar 

  77. Tsilidis KK, Allen NE, Key TJ, et al. Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer. 2011;105(9):1436–42.

    CAS  PubMed  Google Scholar 

  78. Moorman PG, Palmieri RT, Akushevich L, Berchuck A, Schildkraut JM. Ovarian cancer risk factors in African-American and white women. Am J Epidemiol. 2009;170(5):598–606.

    PubMed  Google Scholar 

  79. Annegers JF, Strom H, Decker DG, Dockerty MB, O’Fallon WM. Ovarian cancer: incidence and case-control study. Cancer. 1979;43(2):723–9.

    CAS  PubMed  Google Scholar 

  80. Cramer DW, Hutchison GB, Welch WR, Scully RE, Ryan KJ. Determinants of ovarian cancer risk. I. Reproductive experiences and family history. J Natl Cancer Inst. 1983;71(4):711–6.

    CAS  PubMed  Google Scholar 

  81. Hartge P, Hoover R, McGowan L, Lesher L, Norris HJ. Menopause and ovarian cancer. Am J Epidemiol. 1988;127(5):990–8.

    CAS  PubMed  Google Scholar 

  82. La Vecchia C. Epidemiology of ovarian cancer: a summary review. Eur J Cancer Prev. 2001;10(2):125–9.

    PubMed  Google Scholar 

  83. Joly DJ, Lilienfeld AM, Diamond EL, Bross ID. An epidemiologic study of the relationship of reproductive experience to cancer of the ovary. Am J Epidemiol. 1974;99(3):190–209.

    CAS  PubMed  Google Scholar 

  84. Centers for Disease Control Cancer and Steroid Hormone Study. The reduction in risk of ovarian cancer associated with oral-contraceptive use. N Engl J Med. 1987;316(11):650–5.

    Google Scholar 

  85. Hartge P, Schiffman MH, Hoover R, McGowan L, Lesher L, Norris HJ. A case-control study of epithelial ovarian cancer. Am J Obstet Gynecol. 1989;161(1):10–6.

    CAS  PubMed  Google Scholar 

  86. Nasca PC, Greenwald P, Chorost S, Richart R, Caputo T. An epidemiologic case-control study of ovarian cancer and reproductive factors. Am J Epidemiol. 1984;119(5):705–13.

    CAS  PubMed  Google Scholar 

  87. Adami HO, Hsieh CC, Lambe M, et al. Parity, age at first childbirth, and risk of ovarian cancer. Lancet. 1994;344(8932):1250–4.

    CAS  PubMed  Google Scholar 

  88. La Vecchia C, Decarli A, Franceschi S, Regallo M, Tognoni G. Age at first birth and the risk of epithelial ovarian cancer. J Natl Cancer Inst. 1984;73(3):663–6.

    PubMed  Google Scholar 

  89. Negri E, Franceschi S, Tzonou A, et al. Pooled analysis of 3 European case-control studies: I. Reproductive factors and risk of epithelial ovarian cancer. Int J Cancer. 1991;49(1):50–6.

    CAS  PubMed  Google Scholar 

  90. Franceschi S, La Vecchia C, Helmrich SP, Mangioni C, Tognoni G. Risk factors for epithelial ovarian cancer in Italy. Am J Epidemiol. 1982;115(5):714–9.

    CAS  PubMed  Google Scholar 

  91. Hildreth NG, Kelsey JL, LiVolsi VA, et al. An epidemiologic study of epithelial carcinoma of the ovary. Am J Epidemiol. 1981;114(3):398–405.

    CAS  PubMed  Google Scholar 

  92. John EM, Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of seven U.S. case-control studies. Epithelial ovarian cancer in black women. Collaborative Ovarian Cancer Group. J Natl Cancer Inst. 1993;85(2):142–7.

    CAS  PubMed  Google Scholar 

  93. Bevier M, Sundquist J, Hemminki K. Does the time interval between first and last birth influence the risk of endometrial and ovarian cancer? Eur J Cancer. 2011;47(4):586–91.

    PubMed  Google Scholar 

  94. Chen MT, Cook LS, Daling JR, Weiss NS. Incomplete pregnancies and risk of ovarian cancer (Washington, United States). Cancer Causes Control. 1996;7(4):415–20.

    CAS  PubMed  Google Scholar 

  95. Mori M, Harabuchi I, Miyake H, Casagrande JT, Henderson BE, Ross RK. Reproductive, genetic, and dietary risk factors for ovarian cancer. Am J Epidemiol. 1988;128(4):771–7.

    CAS  PubMed  Google Scholar 

  96. Negri E, Franceschi S, La Vecchia C, Parazzini F. Incomplete pregnancies and ovarian cancer risk. Gynecol Oncol. 1992;47(2):234–8.

    CAS  PubMed  Google Scholar 

  97. Dick ML, Siskind V, Purdie DM, Green AC. Incomplete pregnancy and risk of ovarian cancer: results from two Australian case-control studies and systematic review. Cancer Causes Control. 2009;20(9):1571–85.

    PubMed  Google Scholar 

  98. Mosgaard BJ, Lidegaard O, Kjaer SK, Schou G, Andersen AN. Infertility, fertility drugs, and invasive ovarian cancer: a case-control study. Fertil Steril. 1997;67(6):1005–12.

    CAS  PubMed  Google Scholar 

  99. Modan B, Ron E, Lerner-Geva L, et al. Cancer incidence in a cohort of infertile women. Am J Epidemiol. 1998;147(11):1038–42.

    CAS  PubMed  Google Scholar 

  100. Franceschi S, La Vecchia C, Negri E, et al. Fertility drugs and risk of epithelial ovarian cancer in Italy. Hum Reprod. 1994;9(9):1673–5.

    CAS  PubMed  Google Scholar 

  101. Brinton LA, Sakoda LC, Sherman ME, et al. Relationship of benign gynecologic diseases to subsequent risk of ovarian and uterine tumors. Cancer Epidemiol Biomarkers Prev. 2005;14(12):2929–35.

    PubMed  Google Scholar 

  102. Edmondson RJ, Monaghan JM. The epidemiology of ovarian cancer. Int J Gynecol Cancer. 2001;11(6):423–9.

    CAS  PubMed  Google Scholar 

  103. Vigano P, Somigliana E, Parazzini F, Vercellini P. Bias versus causality: interpreting recent evidence of association between endometriosis and ovarian cancer. Fertil Steril. 2007;88:588–93.

    PubMed  Google Scholar 

  104. Schildkraut JM, Schwingl PJ, Bastos E, Evanoff A, Hughes C. Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet Gynecol. 1996;88(4 Pt 1):554–9.

    CAS  PubMed  Google Scholar 

  105. Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG. Ovarian tumors in a cohort of infertile women. N Engl J Med. 1994;331(12):771–6.

    CAS  PubMed  Google Scholar 

  106. Ness RB, Cramer DW, Goodman MT, et al. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol. 2002;155(3):217–24.

    PubMed  Google Scholar 

  107. Potashnik G, Lerner-Geva L, Genkin L, Chetrit A, Lunenfeld E, Porath A. Fertility drugs and the risk of breast and ovarian cancers: results of a long-term follow-up study. Fertil Steril. 1999;71(5):853–9.

    CAS  PubMed  Google Scholar 

  108. Venn A, Watson L, Lumley J, Giles G, King C, Healy D. Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet. 1995;346(8981):995–1000.

    CAS  PubMed  Google Scholar 

  109. Ayhan A, Salman MC, Celik H, Dursun P, Ozyuncu O, Gultekin M. Association between fertility drugs and gynecologic cancers, breast cancer, and childhood cancers. Acta Obstet Gynecol Scand. 2004;83(12):1104–11.

    PubMed  Google Scholar 

  110. Gwinn ML, Lee NC, Rhodes PH, Layde PM, Rubin GL. Pregnancy, breast feeding, and oral contraceptives and the risk of epithelial ovarian cancer. J Clin Epidemiol. 1990;43(6):559–68.

    CAS  PubMed  Google Scholar 

  111. Rosenblatt KA, Thomas DB. Lactation and the risk of epithelial ovarian cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Epidemiol. 1993;22(2):192–7.

    CAS  PubMed  Google Scholar 

  112. Schneider 2nd AP. Risk factor for ovarian cancer. N Engl J Med. 1987;317(8):508–9.

    PubMed  Google Scholar 

  113. Jordan SJ, Siskind V, C Green A, Whiteman DC, Webb PM. Breastfeeding and risk of epithelial ovarian cancer. Cancer Causes Control. 2010;21(1):109–16.

    PubMed  Google Scholar 

  114. Sayasneh A, Tsivos D, Crawford R. Endometriosis and ovarian cancer: a systematic review. ISRN Obstet Gynecol. 2011;2011:140310.

    PubMed  Google Scholar 

  115. Risch HA, Howe GR. Pelvic inflammatory disease and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 1995;4(5):447–51.

    CAS  PubMed  Google Scholar 

  116. Parazzini F, La Vecchia C, Negri E, Moroni S, Pino D, Fedele L. Pelvic inflammatory disease and risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 1996;5(8):667–9.

    CAS  PubMed  Google Scholar 

  117. Lin HW, Tu YY, Lin SY, et al. Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study. Lancet Oncol. 2011;12(9):900–4.

    PubMed  Google Scholar 

  118. Domchek SM, Rebbeck TR. Prophylactic oophorectomy in women at increased cancer risk. Curr Opin Obstet Gynecol. 2007;19(1):27–30.

    PubMed  Google Scholar 

  119. Green A, Purdie D, Bain C, et al. Tubal sterilisation, hysterectomy and decreased risk of ovarian cancer. Survey of Women’s Health Study Group. Int J Cancer. 1997;71(6):948–51.

    CAS  PubMed  Google Scholar 

  120. Hankinson SE, Hunter DJ, Colditz GA, et al. Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. JAMA. 1993;270(23):2813–8.

    CAS  PubMed  Google Scholar 

  121. Kreiger N, Sloan M, Cotterchio M, Parsons P. Surgical procedures associated with risk of ovarian cancer. Int J Epidemiol. 1997;26(4):710–5.

    CAS  PubMed  Google Scholar 

  122. Miracle-McMahill HL, Calle EE, Kosinski AS, et al. Tubal ligation and fatal ovarian cancer in a large prospective cohort study. Am J Epidemiol. 1997;145(4):349–57.

    CAS  PubMed  Google Scholar 

  123. Rosenblatt KA, Thomas DB. Reduced risk of ovarian cancer in women with a tubal ligation or hysterectomy. The World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Cancer Epidemiol Biomarkers Prev. 1996;5(11):933–5.

    CAS  PubMed  Google Scholar 

  124. Ness RB, Dodge RC, Edwards RP, Baker JA, Moysich KB. Contraception methods, beyond oral contraceptives and tubal ligation, and risk of ovarian cancer. Ann Epidemiol. 2011;21(3):188–96.

    PubMed  Google Scholar 

  125. Cibula D, Widschwendter M, Majek O, Dusek L. Tubal ligation and the risk of ovarian cancer: review and meta-analysis. Hum Reprod Update. 2011;17(1):55–67.

    CAS  PubMed  Google Scholar 

  126. Weiss NS, Harlow BL. Why does hysterectomy without bilateral oophorectomy influence the subsequent incidence of ovarian cancer? Am J Epidemiol. 1986;124(5):856–8.

    CAS  PubMed  Google Scholar 

  127. Chiaffarino F, Parazzini F, Decarli A, et al. Hysterectomy with or without unilateral oophorectomy and risk of ovarian cancer. Gynecol Oncol. 2005;97(2):318–22.

    PubMed  Google Scholar 

  128. Vercellini P, Crosignani P, Somigliana E, et al. The ‘incessant menstruation’ hypothesis: a mechanistic ovarian cancer model with implications for prevention. Hum Reprod. 2011;26(9):2262–73.

    PubMed  Google Scholar 

  129. Gerstman BB, Gross TP, Kennedy DL, Bennett RC, Tomita DK, Stadel BV. Trends in the content and use of oral contraceptives in the United States, 1964–88. Am J Public Health. 1991;81(1):90–6.

    CAS  PubMed  Google Scholar 

  130. Franceschi S, Parazzini F, Negri E, et al. Pooled analysis of 3 European case-control studies of epithelial ovarian cancer: III. Oral contraceptive use. Int J Cancer. 1991;49(1):61–5.

    CAS  PubMed  Google Scholar 

  131. La Vecchia C, Franceschi S. Oral contraceptives and ovarian cancer. Eur J Cancer Prev. 1999;8(4):297–304.

    PubMed  Google Scholar 

  132. Rosenberg L, Palmer JR, Zauber AG, et al. A case-control study of oral contraceptive use and invasive epithelial ovarian cancer. Am J Epidemiol. 1994;139(7):654–61.

    CAS  PubMed  Google Scholar 

  133. Vessey M, Painter R. Oral contraceptive use and cancer. Findings in a large cohort study, 1968–2004. Br J Cancer. 2006;95(3):385–9.

    CAS  PubMed  Google Scholar 

  134. La Vecchia C. Estrogen-progestogen replacement therapy and ovarian cancer: an update. Eur J Cancer Prev. 2006;15(6):490–2.

    PubMed  Google Scholar 

  135. Epithelial ovarian cancer and combined oral contraceptives. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Epidemiol. 1989;18(3):538–45.

    Google Scholar 

  136. Beral V, Hannaford P, Kay C. Oral contraceptive use and malignancies of the genital tract. Results from the Royal College of General Practitioners’ Oral Contraception Study. Lancet. 1988;2(8624):1331–5.

    CAS  PubMed  Google Scholar 

  137. La Vecchia C, Altieri A, Franceschi S, Tavani A. Oral contraceptives and cancer: an update. Drug Saf. 2001;24(10):741–54.

    PubMed  Google Scholar 

  138. Rosenblatt KA, Thomas DB, Noonan EA. High-dose and low-dose combined oral contraceptives: protection against epithelial ovarian cancer and the length of the protective effect. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Eur J Cancer. 1992;28A(11):1872–6.

    CAS  PubMed  Google Scholar 

  139. Ness RB, Grisso JA, Klapper J, et al. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptive. SHARE Study Group. Steroid Hormones and Reproductionss. Am J Epidemiol. 2000;152(3):233–41.

    CAS  PubMed  Google Scholar 

  140. La Vecchia C. Oral contraceptives and ovarian cancer: an update, 1998–2004. Eur J Cancer Prev. 2006;15(2):117–24.

    PubMed  Google Scholar 

  141. Riman T, Dickman PW, Nilsson S, et al. Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study. Am J Epidemiol. 2002;156(4):363–73.

    PubMed  Google Scholar 

  142. Liang AP, Levenson AG, Layde PM, et al. Risk of breast, uterine corpus, and ovarian cancer in women receiving medroxyprogesterone injections. JAMA. 1983;249(21):2909–12.

    CAS  PubMed  Google Scholar 

  143. Wingo PA, Cardinez CJ, Landis SH, et al. Long-term trends in cancer mortality in the United States, 1930–1998. Cancer. 2003;97(12 Suppl):3133–275.

    PubMed  Google Scholar 

  144. Tworoger SS, Fairfield KM, Colditz GA, Rosner BA, Hankinson SE. Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. Am J Epidemiol. 2007;166(8):894–901.

    PubMed  Google Scholar 

  145. Mathur RS, Landgrebe SC, Moody LO, Semmens JP, Williamson HO. The effect of estrogen treatment on plasma concentrations of steroid hormones, gonadotropins, prolactin and sex hormone-binding globulin in post-menopausal women. Maturitas. 1985;7(2):129–33.

    CAS  PubMed  Google Scholar 

  146. Fraser IS. Estrogens and progestogens in clinical practice. London/New York: Churchill Livingstone; 1998.

    Google Scholar 

  147. Riman T, Dickman PW, Nilsson S, et al. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst. 2002;94(7):497–504.

    CAS  PubMed  Google Scholar 

  148. Weiss NS, Lyon JL, Krishnamurthy S, Dietert SE, Liff JM, Daling JR. Noncontraceptive estrogen use and the occurrence of ovarian cancer. J Natl Cancer Inst. 1982;68(1):95–8.

    CAS  PubMed  Google Scholar 

  149. Braem MG, Onland-Moret NC, van den Brandt PA, et al. Reproductive and hormonal factors in association with ovarian cancer in the Netherlands cohort study. Am J Epidemiol. 2010;172(10):1181–9.

    CAS  PubMed  Google Scholar 

  150. Coughlin SS, Giustozzi A, Smith SJ, Lee NC. A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer. J Clin Epidemiol. 2000;53(4):367–75.

    CAS  PubMed  Google Scholar 

  151. Garg PP, Kerlikowske K, Subak L, Grady D. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet Gynecol. 1998;92(3):472–9.

    CAS  PubMed  Google Scholar 

  152. Kaufman DW, Kelly JP, Welch WR, et al. Noncontraceptive estrogen use and epithelial ovarian cancer. Am J Epidemiol. 1989;130(6):1142–51.

    CAS  PubMed  Google Scholar 

  153. Beral V, Bull D, Green J, Reeves G. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet. 2007;369(9574):1703–10.

    CAS  PubMed  Google Scholar 

  154. Pearce CL, Chung K, Pike MC, Wu AH. Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin. Cancer. 2009;115(3):531–9.

    PubMed  Google Scholar 

  155. Greiser CM, Greiser EM, Dören M. Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis. Hum Reprod Update. 2007;13(5):453–63.

    CAS  PubMed  Google Scholar 

  156. Zhou B, Sun Q, Cong R, et al. Hormone replacement therapy and ovarian cancer risk: a meta-analysis. Gynecol Oncol. 2008;108(3):641–51.

    CAS  PubMed  Google Scholar 

  157. Folsom AR, Anderson JP, Ross JA. Estrogen replacement therapy and ovarian cancer. Epidemiology. 2004;15(1):100–4.

    PubMed  Google Scholar 

  158. Lacey Jr JV, Brinton LA, Leitzmann MF, et al. Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort. J Natl Cancer Inst. 2006;98(19):1397–405.

    CAS  PubMed  Google Scholar 

  159. Lacey Jr JV, Mink PJ, Lubin JH, et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA. 2002;288(3):334–41.

    CAS  PubMed  Google Scholar 

  160. Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA. 2001;285(11):1460–5.

    CAS  PubMed  Google Scholar 

  161. Danforth KN, Tworoger SS, Hecht JL, Rosner BA, Colditz GA, Hankinson SE. A prospective study of postmenopausal hormone use and ovarian cancer risk. Br J Cancer. 2007;96(1):151–6.

    CAS  PubMed  Google Scholar 

  162. Hildebrand JS, Gapstur SM, Feigelson HS, Teras LR, Thun MJ, Patel AV. Postmenopausal hormone use and incident ovarian cancer: associations differ by regimen. Int J Cancer. 2010;127(12):2928–35.

    CAS  PubMed  Google Scholar 

  163. Rossing MA, Cushing-Haugen KL, Wicklund KG, Doherty JA, Weiss NS. Menopausal hormone therapy and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(12):2548–56.

    CAS  PubMed  Google Scholar 

  164. Tsilidis KK, Allen NE, Key TJ, et al. Menopausal hormone therapy and risk of ovarian cancer in the European prospective investigation into cancer and nutrition. Cancer Causes Control. 2011;22(8):1075–84.

    PubMed  Google Scholar 

  165. Morch LS, Lokkegaard E, Andreasen AH, Kruger-Kjaer S, Lidegaard O. Hormone therapy and ovarian cancer. JAMA. 2009;302(3):298–305.

    PubMed  Google Scholar 

  166. Canchola AJ, Chang ET, Bernstein L, et al. Body size and the risk of ovarian cancer by hormone therapy use in the California Teachers Study cohort. Cancer Causes Control. 2010;21(12):2241–8.

    PubMed  Google Scholar 

  167. Risch HA. Estrogen replacement therapy and risk of epithelial ovarian cancer. Gynecol Oncol. 1996;63(2):254–7.

    CAS  PubMed  Google Scholar 

  168. Kumar V, Robbins SL. Robbins basic pathology. 8th ed. Philadelphia: Saunders/Elsevier; 2007.

    Google Scholar 

  169. Rodriguez C, Calle EE, Fakhrabadi-Shokoohi D, Jacobs EJ, Thun MJ. Body mass index, height, and the risk of ovarian cancer mortality in a prospective cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2002;11(9):822–8.

    PubMed  Google Scholar 

  170. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569–78.

    PubMed  Google Scholar 

  171. Olsen CM, Green AC, Whiteman DC, Sadeghi S, Kolahdooz F, Webb PM. Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis. Eur J Cancer. 2007;43(4):690–709.

    PubMed  Google Scholar 

  172. Lahmann PH, Cust AE, Friedenreich CM, et al. Anthropometric measures and epithelial ovarian cancer risk in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2010;126(10):2404–15.

    CAS  PubMed  Google Scholar 

  173. Schouten LJ, Rivera C, Hunter DJ, et al. Height, body mass index, and ovarian cancer: a pooled analysis of 12 cohort studies. Cancer Epidemiol Biomarkers Prev. 2008;17(4):902–12.

    PubMed  Google Scholar 

  174. Leitzmann MF, Koebnick C, Danforth KN, et al. Body mass index and risk of ovarian cancer. Cancer. 2009;115(4):812–22.

    PubMed  Google Scholar 

  175. Kotsopoulos J, Baer HJ, Tworoger SS. Anthropometric measures and risk of epithelial ovarian cancer: results from the nurses’ health study. Obesity. 2009;18(8):1625–31.

    PubMed  Google Scholar 

  176. Yang HP, Trabert B, Murphy MA, et al. Ovarian cancer risk factors by histologic subtypes in the NIH‐AARP diet and health study. Int J Cancer. 2012;131(4):938–48.

    CAS  PubMed  Google Scholar 

  177. Schulz M, Lahmann PH, Riboli E, Boeing H. Dietary determinants of epithelial ovarian cancer: a review of the epidemiologic literature. Nutr Cancer. 2004;50(2):120–40.

    PubMed  Google Scholar 

  178. Kolahdooz F, van der Pols JC, Bain CJ, et al. Meat, fish, and ovarian cancer risk: results from 2 Australian case-control studies, a systematic review, and meta-analysis. Am J Clin Nutr. 2010;91(6):1752.

    CAS  PubMed  Google Scholar 

  179. Wallin A, Orsini N, Wolk A. Red and processed meat consumption and risk of ovarian cancer: a dose-response meta-analysis of prospective studies. Br J Cancer. 2011;104(7):1196–201.

    CAS  PubMed  Google Scholar 

  180. Gilsing AMJ, Weijenberg MP, Goldbohm RA, van den Brandt PA, Schouten LJ. Consumption of dietary fat and meat and risk of ovarian cancer in the Netherlands Cohort Study. Am J Clin Nutr. 2011;93(1):118–26.

    CAS  PubMed  Google Scholar 

  181. Oppeneer SJ, Robien K. Tea consumption and epithelial ovarian cancer risk: a systematic review of observational studies. Nutr Cancer. 2011;63(6):817–26.

    CAS  PubMed  Google Scholar 

  182. Larsson SC, Wolk A. Coffee consumption is not associated with ovarian cancer incidence. Cancer Epidemiol Biomarkers Prev. 2005;14(9):2273–4.

    PubMed  Google Scholar 

  183. Riman T, Dickman PW, Nilsson S, Nordlinder H, Magnusson CM, Persson IR. Some life-style factors and the risk of invasive epithelial ovarian cancer in Swedish women. Eur J Epidemiol. 2004;19(11):1011–9.

    PubMed  Google Scholar 

  184. Whittemore AS, Wu ML, Paffenbarger Jr RS, et al. Personal and environmental characteristics related to epithelial ovarian cancer. II. Exposures to talcum powder, tobacco, alcohol, and coffee. Am J Epidemiol. 1988;128(6):1228–40.

    CAS  PubMed  Google Scholar 

  185. Arab L. Epidemiologic evidence on coffee and cancer. Nutr Cancer. 2010;62(3):271–83.

    PubMed  Google Scholar 

  186. Baker JA, Boakye K, McCann SE, et al. Consumption of black tea or coffee and risk of ovarian cancer. Int J Gynecol Cancer. 2007;17(1):50–4.

    CAS  PubMed  Google Scholar 

  187. Nagle CM, Olsen CM, Bain CJ, Whiteman DC, Green AC, Webb PM. Tea consumption and risk of ovarian cancer. Cancer Causes Control. 2010;21(9):1485–91.

    PubMed  Google Scholar 

  188. Holick MF. Vitamin D, deficiency. N Engl J Med. 2007;357(3):266–81.

    CAS  PubMed  Google Scholar 

  189. Zheng W, Danforth KN, Tworoger SS, et al. Circulating 25-hydroxyvitamin D and risk of epithelial ovarian cancer. Am J Epidemiol. 2010;172(1):70.

    PubMed  Google Scholar 

  190. Cook LS, Neilson HK, Lorenzetti DL, Lee RC. A systematic literature review of vitamin D and ovarian cancer. Am J Obstet Gynecol. 2010;203(1):70.e1–8.

    CAS  Google Scholar 

  191. Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H. Meta-analysis: circulating vitamin D and ovarian cancer risk. Gynecol Oncol. 2011;121:369–75.

    CAS  PubMed  Google Scholar 

  192. Tworoger SS, Lee IM, Buring JE, Rosner B, Hollis BW, Hankinson SE. Plasma 25-hydroxyvitamin D and 1, 25-dihydroxyvitamin D and risk of incident ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(4):783–8.

    CAS  PubMed  Google Scholar 

  193. McTiernan A. Mechanisms linking physical activity with cancer. Nat Rev Cancer. 2008;8(3):205–11.

    CAS  PubMed  Google Scholar 

  194. Chionh F, Baglietto L, Krishnan K, et al. Physical activity, body size and composition, and risk of ovarian cancer. Cancer Causes Control. 2010;21(12):2183–94.

    PubMed  Google Scholar 

  195. Bertone ER, Willett WC, Rosner BA, et al. Prospective study of recreational physical activity and ovarian cancer. J Natl Cancer Inst. 2001;93(12):942–8.

    CAS  PubMed  Google Scholar 

  196. Anderson JP, Ross JA, Folsom AR. Anthropometric variables, physical activity, and incidence of ovarian cancer: the Iowa Women’s Health Study. Cancer. 2004;100(7):1515–21.

    PubMed  Google Scholar 

  197. Hannan LM, Leitzmann MF, Lacey Jr JV, et al. Physical activity and risk of ovarian cancer: a prospective cohort study in the United States. Cancer Epidemiol Biomarkers Prev. 2004;13(5):765–70.

    PubMed  Google Scholar 

  198. Schnohr P, Grønbæk M, Petersen L, Ole Hein H, Ia Sørensen T. Physical activity in leisure-time and risk of cancer: 14-year follow-up of 28,000 Danish men and women. Scand J Public Health. 2005;33(4):244–9.

    PubMed  Google Scholar 

  199. Biesma RG, Schouten LJ, Dirx MJ, Goldbohm RA, van den Brandt PA. Physical activity and risk of ovarian cancer: results from the Netherlands Cohort Study (The Netherlands). Cancer Causes Control. 2006;17(1):109–15.

    PubMed  Google Scholar 

  200. Patel AV, Rodriguez C, Pavluck AL, Thun MJ, Calle EE. Recreational physical activity and sedentary behavior in relation to ovarian cancer risk in a large cohort of US women. Am J Epidemiol. 2006;163(8):709.

    PubMed  Google Scholar 

  201. Weiderpass E, Margolis KL, Sandin S, et al. Prospective study of physical activity in different periods of life and the risk of ovarian cancer. Int J Cancer. 2006;118(12):3153–60.

    CAS  PubMed  Google Scholar 

  202. Lahmann PH, Friedenreich C, Schulz M, et al. Physical activity and ovarian cancer risk: the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev. 2009;18(1):351–4.

    PubMed  Google Scholar 

  203. Leitzmann MF, Koebnick C, Moore SC, et al. Prospective study of physical activity and the risk of ovarian cancer. Cancer Causes Control. 2009;20(5):765–73.

    PubMed  Google Scholar 

  204. Pukkala E, Poskiparta M, Apter D, Vihko V. Life-long physical activity and cancer risk among Finnish female teachers. Eur J Cancer Prev. 1993;2(5):369.

    CAS  PubMed  Google Scholar 

  205. Zheng W, Shu XO, Gao YT, McLaughlin JK, Chow WH, Blot WJ. Occupational physical activity and the incidence of cancer of the breast, corpus uteri, and ovary in Shanghai. Cancer. 1993;71(11):3620–4.

    CAS  PubMed  Google Scholar 

  206. Moorman PG, Jones LW, Akushevich L, Schildkraut JM. Recreational physical activity and ovarian cancer risk and survival. Ann Epidemiol. 2011;21(3):178–87.

    PubMed  Google Scholar 

  207. Cottreau CM, Ness RB, Kriska AM. Physical activity and reduced risk of ovarian cancer. Obstet Gynecol. 2000;96(4):609.

    CAS  PubMed  Google Scholar 

  208. Bertone ER, Newcomb PA, Willett WC, Stampfer MJ, Egan KM. Recreational physical activity and ovarian cancer in a population‐based case‐control study. Int J Cancer. 2002;99(3):431–6.

    CAS  PubMed  Google Scholar 

  209. Pan SY, Ugnat AM, Mao Y. Physical activity and the risk of ovarian cancer: a case‐control study in Canada. Int J Cancer. 2005;117(2):300–7.

    CAS  PubMed  Google Scholar 

  210. Olsen CM, Bain CJ, Jordan SJ, et al. Recreational physical activity and epithelial ovarian cancer: a case-control study, systematic review, and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2007;16(11):2321–30.

    PubMed  Google Scholar 

  211. Carnide N, Kreiger N, Cotterchio M. Association between frequency and intensity of recreational physical activity and epithelial ovarian cancer risk by age period. Eur J Cancer Prev. 2009;18(4):322.

    PubMed  Google Scholar 

  212. Rossing MA, Cushing-Haugen KL, Wicklund KG, Doherty JA, Weiss NS. Recreational physical activity and risk of epithelial ovarian cancer. Cancer Causes Control. 2010;21(4):485–91.

    PubMed  Google Scholar 

  213. Tavani A, Gallus S, La Vecchia C, et al. Physical activity and risk of ovarian cancer: an Italian case-control study. Int J Cancer. 2001;91(3):407–11.

    CAS  PubMed  Google Scholar 

  214. Dosemeci M, Hayes RB, Vetter R, et al. Occupational physical activity, socioeconomic status, and risks of 15 cancer sites in Turkey. Cancer Causes Control. 1993;4(4):313–21.

    CAS  PubMed  Google Scholar 

  215. Zhang M, Lee AH, Binns CW. Physical activity and epithelial ovarian cancer risk: a case‐control study in China. Int J Cancer. 2003;105(6):838–43.

    CAS  PubMed  Google Scholar 

  216. Zhang M, Xie X, Lee AH, Binns CW. Sedentary behaviours and epithelial ovarian cancer risk. Cancer Causes Control. 2004;15(1):83–9.

    PubMed  Google Scholar 

  217. Franks AL, Lee NC, Kendrick JS, Rubin GL, Layde PM. Cigarette smoking and the risk of epithelial ovarian cancer. Am J Epidemiol. 1987;126(1):112–7.

    CAS  PubMed  Google Scholar 

  218. Smith EM, Sowers MF, Burns TL. Effects of smoking on the development of female reproductive cancers. J Natl Cancer Inst. 1984;73(2):371–6.

    CAS  PubMed  Google Scholar 

  219. Modugno F, Ness RB, Cottreau CM. Cigarette smoking and the risk of mucinous and nonmucinous epithelial ovarian cancer. Epidemiology. 2002;13(4):467–71.

    PubMed  Google Scholar 

  220. Jordan SJ, Whiteman DC, Purdie DM, Green AC, Webb PM. Does smoking increase risk of ovarian cancer? A systematic review. Gynecol Oncol. 2006;103(3):1122–9.

    CAS  PubMed  Google Scholar 

  221. Rossing MA, Cushing-Haugen KL, Wicklund KG, Weiss NS. Cigarette smoking and risk of epithelial ovarian cancer. Cancer Causes Control. 2008;19(4):413–20.

    PubMed  Google Scholar 

  222. Gwinn ML, Webster LA, Lee NC, Layde PM, Rubin GL. Alcohol consumption and ovarian cancer risk. Am J Epidemiol. 1986;123(5):759–66.

    CAS  PubMed  Google Scholar 

  223. Adami HO, McLaughlin JK, Hsing AW, et al. Alcoholism and cancer risk: a population-based cohort study. Cancer Causes Control. 1992;3(5):419–25.

    CAS  PubMed  Google Scholar 

  224. Larsson SC, Wolk A. Wine consumption and epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2004;13(11 Pt 1):1823; author reply 1823–4.

    PubMed  Google Scholar 

  225. Modugno F, Ness RB, Allen GO. Alcohol consumption and the risk of mucinous and nonmucinous epithelial ovarian cancer. Obstet Gynecol. 2003;102(6):1336–43.

    CAS  PubMed  Google Scholar 

  226. Goodman MT, Tung KH. Alcohol consumption and the risk of borderline and invasive ovarian cancer. Obstet Gynecol. 2003;101(6):1221–8.

    CAS  PubMed  Google Scholar 

  227. Kelemen LE, Sellers TA, Vierkant RA, Harnack L, Cerhan JR. Association of folate and alcohol with risk of ovarian cancer in a prospective study of postmenopausal women. Cancer Causes Control. 2004;15(10):1085–93.

    PubMed  Google Scholar 

  228. Webb PM, Purdie DM, Bain CJ, Green AC. Alcohol, wine, and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2004;13(4):592–9.

    CAS  PubMed  Google Scholar 

  229. Peterson NB, Trentham-Dietz A, Newcomb PA, et al. Alcohol consumption and ovarian cancer risk in a population-based case-control study. Int J Cancer. 2006;119(10):2423–7.

    CAS  PubMed  Google Scholar 

  230. Schouten LJ, Zeegers MP, Goldbohm RA, van den Brandt PA. Alcohol and ovarian cancer risk: results from the Netherlands Cohort Study. Cancer Causes Control. 2004;15(2):201–9.

    PubMed  Google Scholar 

  231. Genkinger JM, Hunter DJ, Spiegelman D, et al. Alcohol intake and ovarian cancer risk: a pooled analysis of 10 cohort studies. Br J Cancer. 2006;94(5):757–62.

    CAS  PubMed  Google Scholar 

  232. Kim HS, Kim JW, Shouten LJ, et al. Wine drinking and epithelial ovarian cancer risk: a meta-analysis. J Gynecol Oncol. 2010;21(2):112–8.

    PubMed  Google Scholar 

  233. Shen N, Weiderpass E, Antilla A, et al. Epidemiology of occupational and environmental risk factors related to ovarian cancer. Scand J Work Environ Health. 1998;24(3):175–82.

    CAS  PubMed  Google Scholar 

  234. Shields T, Gridley G, Moradi T, Adami J, Plato N, Dosemeci M. Occupational exposures and the risk of ovarian cancer in Sweden. Am J Ind Med. 2002;42(3):200–13.

    PubMed  Google Scholar 

  235. Heller DS, Gordon RE, Westhoff C, Gerber S. Asbestos exposure and ovarian fiber burden. Am J Ind Med. 1996;29(5):435–9.

    CAS  PubMed  Google Scholar 

  236. Langseth H, Johansen BV, Nesland JM, Kjaerheim K. Asbestos fibers in ovarian tissue from Norwegian pulp and paper workers. Int J Gynecol Cancer. 2007;17(1):44–9.

    CAS  PubMed  Google Scholar 

  237. Roggli VL. Experimental models of asbestos-related diseases. In: Rogglie VL, Greenberg SD, Pratt PC, editors. Pathology of asbestos-associated diseases. Boston: Little Brown & Company; 1992.

    Google Scholar 

  238. Reid A, de Klerk N, Musk AW. Does exposure to asbestos cause ovarian cancer? A systematic literature review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2011;20(7):1287–95.

    CAS  PubMed  Google Scholar 

  239. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Overall evaluations of carcinogenicity: an updating of IARC monographs supplement 7. International Agency for Research on Cancer, Lyon; 1987.

    Google Scholar 

  240. Huncharek M, Geschwind JF, Kupelnick B. Perineal application of cosmetic talc and risk of invasive epithelial ovarian cancer: a meta-analysis of 11,933 subjects from sixteen observational studies. Anticancer Res. 2003;23(2C):1955–60.

    PubMed  Google Scholar 

  241. Gates MA, Tworoger SS, Terry KL, et al. Talc use, variants of the GSTM1, GSTT1, and NAT2 genes, and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2008;17(9):2436–44.

    CAS  PubMed  Google Scholar 

  242. Muscat JE, Huncharek MS. Perineal talc use and ovarian cancer: a critical review. Eur J Cancer Prev. 2008;17(2):139–46.

    PubMed  Google Scholar 

  243. Turner MC, Chen Y, Krewski D, Ghadirian P. An overview of the association between allergy and cancer. Int J Cancer. 2006;118(12):3124–32.

    CAS  PubMed  Google Scholar 

  244. Elmasri WM, Tran TH, Mulla ZD. A case-control study of asthma and ovarian cancer. Arch Environ Occup Health. 2010;65(2):101–5.

    PubMed  Google Scholar 

  245. Pinheiro SP, Tworoger SS, Cramer DW, Rosner BA, Hankinson SE. Use of nonsteroidal antiinflammatory agents and incidence of ovarian cancer in 2 large prospective cohorts. Am J Epidemiol. 2009;169(11):1378–87.

    PubMed  Google Scholar 

  246. Prizment AE, Folsom AR, Anderson KE. Nonsteroidal anti-inflammatory drugs and risk for ovarian and endometrial cancers in the Iowa Women’s Health Study. Cancer Epidemiol Biomarkers Prev. 2010;19(2):435–42.

    CAS  PubMed  Google Scholar 

  247. Li D. Metformin as an antitumor agent in cancer prevention and treatment. J Diabetes. 2011;3(4):320–7.

    CAS  PubMed  Google Scholar 

  248. Bodmer M, Becker C, Meier C, Jick SS, Meier CR. Use of metformin and the risk of ovarian cancer: a case-control analysis. Gynecol Oncol. 2011;123:200–4.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Population Sciences, Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, MRC CAN-CONT, Tampa, FL, 33612, USA

    Jennifer Permuth-Wey PhD, Andrea Besharat MPH & Thomas A. Sellers PhD

Authors
  1. Jennifer Permuth-Wey PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrea Besharat MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thomas A. Sellers PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas A. Sellers PhD .

Editor information

Editors and Affiliations

  1. Department of Obstetrics and Gynecology, Weill Cornell Medical College, The New York Presbyterian Hospital-Weill Cornell Medical Center, Cornell University, New York, USA

    Samir A. Farghaly

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Permuth-Wey, J., Besharat, A., Sellers, T.A. (2014). Epidemiology of Ovarian Cancer: An Update. In: Farghaly, S. (eds) Advances in Diagnosis and Management of Ovarian Cancer. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-8271-0_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-8271-0_1

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4614-8270-3

  • Online ISBN: 978-1-4614-8271-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation